Immunogen (FRA:IMU) Additional Paid-In Capital : €2,124.9 Mil(As of Sep. 2023)

View and export this data going back to . Start your Free Trial

What is Immunogen Additional Paid-In Capital?

Immunogen's quarterly additional paid-in capital increased from Mar. 2023 (€1,732.3 Mil) to Jun. 2023 (€2,056.3 Mil) and increased from Jun. 2023 (€2,056.3 Mil) to Sep. 2023 (€2,124.9 Mil).

Immunogen's annual additional paid-in capital increased from Dec. 2020 (€1,166.8 Mil) to Dec. 2021 (€1,588.2 Mil) and increased from Dec. 2021 (€1,588.2 Mil) to Dec. 2022 (€1,744.2 Mil).

Immunogen Additional Paid-In Capital Historical Data

The historical data trend for Immunogen's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunogen Additional Paid-In Capital Chart

Immunogen Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Additional Paid-In Capital

Get a 7-Day Free Trial

1,048.48

1,088.86

1,166.80

1,588.16

1,744.17

Immunogen Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Additional Paid-In Capital	Get a 7-Day Free Trial															1,828.97	1,744.17	1,732.33	2,056.26	2,124.88

Immunogen Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Immunogen Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Immunogen's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunogen (FRA:IMU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunogen Inc (FRA:IMU) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

IMGN:USA IMGN:Mexico

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.immunogen.com

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent.

Immunogen (FRA:IMU) Headlines

No Headlines